Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 1/2 3Phase 2/3 2Phase 3 1Phase 1 1

Status

Terminated 1Recruiting 1

Sponsor Class

OTHER_GOV 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Gynecologic 2

Conditions

Uterine Cervical Neoplasms 2NSCLC 1Esophageal Squamous Cell Carcinoma 1Endometrial Neoplasms 1Colorectal Neoplasms 1Advanced Solid Tumor 1

Interventions

Cisplatin 6Carboplatin 3spartalizumab 2Paclitaxel 2Drug Therapy 2Bevacizumab 2pembrolizumab 1netupitant, palosentron drug combination 1lenvatinib 1cyclopropapyrroloindole 1camrelizumab 1Vaccines, Synthetic 1Taxes 1Radiotherapy, Intensity-Modulated 1Radiotherapy 1Radiation 1Metronidazole 1Injections 1Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18 1Docetaxel 1Dexamethasone 1Control Groups 1Brachytherapy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2/3 × Uterine Cervical Neoplasms × spartalizumab × Clear all
NCT07472153 2026-05-28

PD-1 (Programmed Death-1) Versus PD-L1 (Programmed Death-ligand 1) Immune Check Point Inhibitors Combined With Chemotherapy, With or Without Bevacizumab, In Patients With Metastatic, Persistent Or Recurrent Cervical Cancer

N.N. Alexandrov National Cancer Centre

Phase 2/3 Recruiting
120 enrolled
Gynecologic

Uterine Cervical Neoplasms

NCT04864782 2024-01-12

QL1604 Plus Chemotherapy in Subjects With Stage IVB, Recurrent, or Metastatic Cervical Cancer

Qilu Pharmaceutical Co., Ltd.

Phase 2/3 Terminated
46 enrolled
Gynecologic

Uterine Cervical Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡